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Summary 
CD44H is the principal cell surface receptor for hyaluronate, which is a major glycosaminoglycan 
of the  extraceUular  matrix.  Expression of CD44H  is  enhanced in  a  variety  of malignant 
tumors and correlates with tumor aggressiveness, supporting the notion that interaction between 
CD44H and hyaluronate may play an important role in tumor growth and dissemination. In 
this report we show that in vivo tumor formation by human lymphoma Namalwa cells, stably 
transfected with CD44H, can be suppressed by a soluble human CD44H-immunoglobulin fusion 
protein. Disruption of the interaction between CD44H and its physiologic ligands may provide 
a novel strategy for controlling tumor growth in vivo. 
C 
d44/Pgp-1 is a cell surface glycoprotein that plays a role 
in lymphocyte migration, cell-call adhesion, and cell- 
substrate interaction (1-4).  At least two isoforms of CD44 
expressed in human cells have been identified: an 80-90 kD 
form called CD44H with high affinity for hyaluronate (5-7), 
expressed mainly on hematopoietic and other cells of mesen- 
chymal origin, and a 130-150-kD form, CD44E, expressed 
predominantly on epithelial cell subsets,  with little or no 
affinity for surface-bound hyaluronate (8,  9). 
Several lines of evidence suggest a role for CD44H and 
hyaluronate in tumor growth and metastasis. Carcinomas are 
commonly associated with local accumulation of hyaluronate 
(10, 11), and angiogenesis, which is essential for malignant 
growth and spread, is thought to be promoted by hyaluronic 
acid degradation products (12). Aggressiveness of certain car- 
cinomas correlates with their ability to induce formation of 
hyaluronate in situ (13), and highly invasive human bladder 
carcinoma cells express high levels of hyaluronate receptors 
(14). In human non-Hodgkin's lymphomas, high expression 
of CD44 is associated with aggressive behavior,  dissemina- 
tion, and poor prognosis (15). 
Recently, the Burkitt lymphoma Namalwa, stably trans- 
fected with human CD44H cDNA, was found to display 
increased tumorigenicity and metastatic proclivity in nude 
mice with respect to the CD44H-  parental cell line (16). 
This observation was suggested to be the consequence of 
CD44H +  cell  attachment  to  extracellular  matrix-(ECM) 
bound hyaluronate, resulting in tumor cell anchorage in host 
tissues and access to growth factors sequestered in the ECM 
(17). Hyaluronate is proposed to provide a molecular bridge 
for interactions between tumor cells and host tissue stromal 
cells which are believed to generate production of growth 
and angiogenic factors beneficial to tumor growth (10-12, 
16). However, the possibility that CD44H may mediate cel- 
lular interactions with other, unidentified ligands, which may 
directly promote tumor development, has not been excluded. 
Unlike CD44H,  expression of CD44E in Burkitt lym- 
phomas was not associated with enhanced tumorigenicity (16). 
Recently, the coexpression of CD44H and a novel CD44 iso- 
form, distinct from CD44E, was reported to confer metastatic 
potential to rat mammary and pancreatic carcinoma cell lines 
(18). Subsequent studies have suggested that several additional 
isoforms of CD44 may exist as a result of differential splicing 
of five exons encoding a segment of the extracellular domain 
(19). The role of CD44 in tumor growth and metastasis may 
therefore depend on the isoform of CD44 expressed, the na- 
ture of tumor cells, and the type of host tissue microen- 
vironment. 
Based on the above observations, and the notion that some 
antibodies to CD44 block attachment to hyaluronate (7), it 
would appear likely that growth of CD44H + tumor cells 
in vivo may be altered by disrupting the interaction between 
CD44H and its ligands.  To explore this possibility,  we in- 
jected  soluble  CD44H-immunoglobulin (called  receptor- 
globulins or CD44Rg)  fusion proteins (6)  together with 
CD44H + and CD44H-  lymphoma cells into nude mice, 
with the premise that soluble CD44H should occupy CD44H 
ligands, thereby blocking CD44H + tumor cell attachment 
to ECM. 
Materials and Methods 
Preparation of Soluble CD44Rg.  CD44Rg and CD8Rg (used 
as a control) were prepared as previously  described  (6). Briefly, syn- 
thetic oligonucleotide-primed amplification of cDNA sequences 
encoding the extracellular domain of CD44H or CD8 was per- 
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donuclease restriction sites to facilitate subsequent insertion of 
amplified sequences into Ig expression vectors (6). Amplified se- 
quences were subjected to appropriate restriction enzyme diges- 
tion and ligated to Ig vectors  previously  subjected  to corresponding 
endonuclease cleavage. CD44Rg and CD8Rg vectors were intro- 
duced into COS cells  by the DEAE-Dextran method (6), and 5-7 d 
posttransfection, superuatants were harvested and Rg molecules 
purified on Protein A trisacryl beads (Pierce Chemical Co., Rock- 
ford, IL). CD44Rg and CD8Rg fusion proteins were eluted with 
0.1 M acetic acid pH 4.5, dialyzed overnight, and purified protein 
concentration determined in ELISA assays. Typically 1-3/zg of 
Rg/ml of supernatant were obtained. 
Cell Lines.  Development  of stable CD44 transfectants in the 
human Burkitt lymphoma cell line Namalwa was described previ- 
ously (8, 16). CD44 N.2 transfectants, selected  for high expression 
of CD44H (16), were  maintained in DMEM, (Gibco Laboratories, 
Grand Island, NY) supplemented with 10% fetal bovine serum 
(Gibco Laboratories), gentamycin, and 500/~g/ml hygromycin 
(Sigma Chemical  Co., St. Louis,  MO). Cells were periodically  tested 
for conservation of CD44 expression by indirect immunofluores- 
cence using anti-CD44  mAb  F-10-44-2 (Accurate Chemical & 
Scientific  Corp., Westbury, NY), and affinity-purified,  FITC-labeled 
goat anti-mouse antibody (Cappel Laboratories,  Malvern, PA). An- 
tibody reactivity was analyzed on a fluorescence  activated analyzer 
(Becton Dickinson & Co., Mountain View, CA). 
Determination of the Effect of CD44Rg Reactivity with Transfectants 
and the Effect of CD44Rg on Transfectant  and Parental Cell Growth 
In Vitro.  5  x  104 tumor cells were cultured per well in RPMI 
medium (Gibco Laboratories) supplemented with 10% FCS, gen- 
tamycin, and 1% t-glutamine in 96-we11, flat-bottomed microtiter 
plates (Falcon, Lincoln Park, NJ) for 24 h. Purified CD44Rg or 
CD8Rg were added to the wells at the beginning of the culture 
period at concentrations of 12, 25, and 50 #g/ml. After the 24-h 
culture period, cells were pulsed with 1/zCi of [3H]thymidine  for 
4 h. Ceils were then washed, harvested with an automatic PH.D. 
harvester (Cambridge Bioscience, Cambridge, MA), and 3H incor- 
poration determined. All cultures were done in triplicate. In addi- 
tion, transfectants and parental cell lines were tested for possible 
binding of CD44Rg by indirect immunofluorescence.  Cells were 
incubated with CD44Rg at concentrations ranging from 2-20 
/~g/ml on ice for 1 h, washed in PBS, incubated with an affinity- 
purified goat anti-human, fluorescein-labeled  antibody for 30 rain 
on ice, washed, fixed in 4%  formaldehyde, and examined for 
CD44Rg binding on a FACS  |  (Becton Dickinson & Co.). 
Determination of In Vivo Half-life of CD44 and CD8Rg.  Two 
groups of  6-8-wk old female  BALB/c  (nu/nu) mice (6/group) were 
injected with 500/zg of  puriiied CD44Rg or CDSRg intravenously. 
Serum samples were obtained from individual  mice at various times 
after injection. At every time point, mice from which serum had 
been obtained were killed for immunohistological tissue examina- 
tion. The concentration of CD44Rg and CD8Rg was determined 
in an ELISA specific for CD44 and CD8Rg, respectively.  Briefly, 
96-well ELISA  plates were coated with 0.5 mg/ml ofa monoclonal 
anti-CD44 antibody (A3) or a monoclonal anti-CD8 (OKT8) an- 
tibody. Serum samples from individual mice were diluted (1:10) 
with PBS and added to the plates. The second step was performed 
with  an  affinity-purified alkaline phophatase-conjugated goat 
anti-human,  IgG-specific  antibody (Southern Biotechnology As- 
sociates, Birmingham, AL). This assay  was found to detect between 
1 and 10 ng of CD44Rg or CD8Rg. 
Introduction of Tumor Cells and Rg Molecules into Animals  and 
Monitoring of Tumor Growth.  CD44 + N2.1 tumor cells, resus- 
pended at a concentration of 1.7  x  10Vml either in PBS con- 
taining 300 #g/ml of CD44Rg or in PBS alone were injected 
intravenously  into two groups of  BALB/c  (nu/nu) mice, Each mouse 
received 5.1  x  106 N.2.1 tumor cells in 0.3 ml (five  mice received 
cells in PBS and six mice received CD44Rg).  Three subsequent 
daily injections of either PBS alone or CD44Rg (300/~g) in PBS 
were administered. Tumor growth was determined by measuring 
the concentration of human IgM in the serum of nude mice with 
a human  IgM-specific ELISA as described previously (16), and 
confirmed by histological examination of organs at autopsy. 
In a second set of experiments, CD44 + N2,1 tumor ceils were 
resuspended at 1.7  x  107/ml in PBS containing either 500/zg/ml 
of CD44Rg, or 500 ~g/ml of CD8Rg or in PBS alone, and were 
injected intravenously  into three groups of BALB/c (nu/nu) mice. 
Each mouse received 5.1  x  104 N.2.1 tumor cells in 0.3 ml., as 
above, and three more daily injections of PBS alone (four mice), 
PBS with CD44Rg or CD8Rg (500/~g, 5 mice) were administered. 
Tumor growth was determined as above. 
Parental, CD44-  Namalwa cells were resuspended at  1.7  x 
107/ml in  PBS containing 500 #g/ml of sCD44-Ig or in  PBS 
alone, and were injected intravenously  into two groups of  BALB/c 
(nu/nu) mice. Each mouse received 5.1  x  106 Namalwa cells in 
a 0.3 ml volume. Subsequent injections and tumor growth evalua- 
tion were performed as above. 
Results and Discussion 
CD44Rg  and CD8Rg  Do Not Alter  CD44 + or CD44- 
Namalwa Cell Growth In  Vitra  CD44Rg was prepared by 
ligating cDNA sequences encoding the extracellular domain 
of human CD44H to genomic sequences encoding the Fc 
region of  human IgG, as described (6). Soluble human CDSRg 
(6) was used as a control. To determine whether CD44Rg 
might interfere with growth of CD44 § tumor cells in vitro, 
CD44H +  cells  derived  from a  Namalwa CD44.5  tumor 
grown in subcutaneous tissues  of a nude mouse (16) were 
selected for the highest level of CD44H expression  by lim- 
iting dilution. A CD44H + subclone, N2.1, was isolated that 
expresses at least a 10-fold greater amount of surface CD44H 
than the parental cell line Namalwa-CD44.5, as determined 
by indirect immunofluorescent staining with a monoclonal 
anti-CD44 antibody (data not shown). N2.1 was cultured 
in vitro in the presence of various concentrations of CD44Rg 
or CD8Rg. After 24 h in culture, cells were pulsed with 
[3H]thymidine and harvested 4 h later. Neither CDSRg nor 
CD44Rg altered the growth of CD44 + N2.1  or CD44- 
Namalwa cells in vitro (data not shown), and neither reagent 
bound to either cell line as assessed  by indirect immunofluores- 
cence  (data not shown).  These observations indicate that 
CD44Rg  does  not  react  directly with  N2.1  or  parental 
Namalwa cells, and that its presence does not affect growth 
of either cell line in vitro. Any effect on tumor cell growth 
in vivo would therefore not be the result of CD44Rg inter- 
action with  the  tumor cells,  but  rather  from  CD44Rg- 
mediated inhibition of tumor cell binding to substrate as a 
result of competition for specific binding sites. 
Determination  of the In Vivo Half-life of Rg Molecules.  Be- 
fore investigating whether CD44Rg can block tumor growth 
in  vivo,  we  determined  the  half-life  and  distribution  of 
CD44Rg in nude mice after intravenous administration. Two 
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with 100/~g of CD44Kg or CDSILg per mouse. Animals 
were bled at various time points after injection and serum 
levels of CD44Rg and CDSRg determined using an ELISA 
specific for CD44Kg and CD8Rg, respectively. The ELISA 
assay allowed detection of as little as 1-10 ng of CD44ILg 
or CDSKg in the serum. The half-life of CD44Rg in nude 
mice ranged from 60 to 90 rain (Fig. 1). In contrast, the half- 
life of CD8Rg was about 40 h. In an attempt to determine 
tissue penetration of the Rg molecules, we performed im- 
munohistological staining for CD44ILg and CD8Kg in var- 
ious tissues after in vivo injection. 2 h after injection, CD44ILg 
could be detected in organs that have a hyaluronate-rich ECM 
(6),  the most intense staining being localized to the renal 
papilla (data not shown). In contrast, CD8Kg was not de- 
tected in any of these tissues by indirect immunofluorescence. 
The failure to detect CD8tLg by this approach does not ex- 
clude the possibility that soluble CD8 might penetrate tissues 
when injected intravenously, but suggests that CDSKg does 
not recognize ligands in the tissues examined, which is con- 
sistent with earlier observations (6). These experiments pro- 
vide evidence that intravenous injection of CD44Rg results 
in rapid removal of the fusion protein from the circulation, 
and suggest that the short serum half-life  of  CD44Kg is most 
likely due to its retention in tissues expressing specific  ligands. 
CIM4Rg Inhibits Dissemination and Growth of CD44* Lym- 
phoma  Cells.  We  next  attempted to  determine whether 
administration of CD44ILg  could block CD44H +  N2.1 
tumor cell growth in vivo. In the first set of experiments, 
CD44H +  N2.1  tumor ceils were resuspended  at  1.7  x 
107/ml either in PBS containing 300 #g/m1 of CD44Rg or 
in PBS alone, and were then injected intravenously into two 
separate groups of nude mice. Each mouse received 5  x  106 
N2.1 tumor cells in a 0.3  ml suspension.  Initial  injection 
was followed by one additional injection a day for 3 d of ei- 
ther PBS alone or PBS with 300/~g CD44Rg. Tumor growth 
was assessed  by the quantitating Namalwa call-derived  human 
IgM in the serum of nude mice, based on the earlier observa- 
tion that Namalwa cell-derived solid tumor growth was con- 
sistently  associated with detectable  levels of human IgM 
Table  1.  Tissue  Distribution of Metastases derived  from Animals 
Injected with N2.1 with PBS or CD44Rg or CDSRg 
Number of animals with metastases 
Tissue  PBS (8/9)  CD8Rg(4/5)  CD44Rg(3/ll) 
Bone marrow  8  4  3 
Spleen  0  0  0 
Kidney  2  0  0 
Peritoneum  4  1  0 
Gut  1  0  0 
Combined results from both sets of experiments, at 300 and 500 ~g of 
CD441~g/injection are presented. The fraction of injected animals that 
developed tumor growth in each group is indicated in brackets. All three 
animals in the CD441Lg group which developed tumors had received the 
lower dose (300/~g)  of CD44R.g/injection. 
in  routine serum (16). This  allowed  early  detection and 
monitoring of tumor growth. However, in the event that 
certain tumors might lose the ability to secrete IgM, an au- 
topsy was performed on all animals that died during the course 
of the experiments, and tumor presence confirmed by gross 
and histological examination (Table 1). All surviving animals 
were killed 100-130 d after initial tumor injection, and tissues 
examined for evidence of tumor growth. Tumor growth was 
significantly delayed and fewer animals developed tumors in 
the CD44Rg-treated group. 6 wk after tumor cell injection, 
80% of the animals that had received N2.1 in PBS alone had 
died. In contrast, only one mouse receiving N2.1 and CD44Rg 
developed detectable tumor growth. 3 mo after tumor injec- 
tion, two additional  animals treated with CD44tLg  devel- 
oped tumors (Fig. 2 A). 
In a second set of experiments,  we increased the dosage 
of CD44Rg to 500/xg/injection and included an additional 
control group in which animals were injected with an iden- 
tical number of tumor cells and 500/~g of CD8tLg (Fig. 2 
B). All animals that had received CD8tLg,  and 80% of the 
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Figure 1.  Comparison of the serum half life of CD44Rg 
(sCD44-KIg) and CDSKg (sCD8-RIg).  Serum concentra- 
tion of each Rg molecule was determined using an ELISA 
assay and the concentration expressed in mmoles. tO0' 
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Figure 2.  Tumor development in nude mice as a result of intravenous 
CD44 + and CD44-  tumor cell injection in the presence or absence of 
soluble CD44 (sCD44) or soluble CD8 (sCD8). (A) Comparison of the 
rate  of tumor  development  in mice  injected  with  equal  numbers of 
CD44 + transfectants in the presence and absence of 300 9g of CD44Rg 
(sCD44). (B) Comparison of the rate of tumor development in animals 
injected with equal numbers of CD44 + tumor cells in the presence of 
500 #g of CD44Rg (sCD44), CD8Rg (sCDS), or in PBS alone. (C) Com- 
parison of the rate of tumor development in animals injected with the 
parental  CD44-  cell  line in  the  presence and  absence  of CD44Rg 
(sCD44). 
animals that had received PBS died within 10 wk of tumor 
cell injection. However, none of the animals that had received 
CD44Rg revealed detectable tumor growth, even 100 d after 
the initial tumor cell injection (Table 1). These observations 
provide evidence that CD44Rg specifically inhibits N2.1 cell- 
derived tumor growth in nude mice. 
However, similar experiments revealed that CD44Rg did 
not delay or block the development of tumors in animals in- 
jected with parental CD44- Namalwa cells (Fig. 2 C). The 
effects of CD44Rg are therefore most likely due to its ability 
to block interaction between CD44H on tumor cells and its 
ligands in host tissues. 
CD44Rg appeared to be much more effective in retarding 
tumor growth than we had originally anticipated. In recent 
work, we reported that both parental Namalwa cells and 
Namalwa CD44H § transfectants produced tumors when in- 
jected either subcutaneously or intravenously into nude mice 
(16). However,  CD44H + Namalwa transfectants  produced 
tumors more rapidly and consistently than the parental celI 
line, while displaying a similar pattern of hematogenous dis- 
semination. These observations were consistent with the no- 
tion that CD44H expression  in lymphoma cells may pro- 
mote the initiation of tumor growth, but may not be essential 
for tumor development. Based on these results, we had an- 
ticipated that administration of CD44Rg might reduce the 
in vivo growth rate of N2.I tumors to the level of the pa- 
rental cell-derived tumors. It is surprising, that CD44Rg was 
found to retard the growth of intravenously administered N2.1 
tumor cells to a rate significantly lower than that of CD44- 
Namalwa tumors (Fig. 2, A  and B). 10 wk after tumor in- 
jection,  most  of the  animals  that  had  received  CD44- 
Namalwa calls, with or without CD44Rg, had devdoped 
tumors or died. No tumors, on the other hand, were ob- 
served in any of the animals injected with N2.1 cells and 500 
/~g of CD44Rg. Absence of tumor growth in these animals 
was confirmed at the macroscopic and microscopic level in 
all major organs. These observations raise the possibility that 
expression of CD44H may interfere with expression or func- 
tional ECM binding capacity of other, constitutive Namalwa 
cell surface receptors. High CD44H expressors, such as N2.1 
cells, may therefore display an increased dependence on CD44H 
for interaction with the host tissue microenvironment and 
tumor formation. 
Dissemination and metastatic growth of tumors are com- 
plex processes in which expression of several classes of adhe- 
sion molecules, which regulate tumor cell interaction with 
endothelium and ECM, play a major role (17, 20,  21). In 
the natural evolution of malignancies, only a fraction of cells 
that constitute the primary tumor are believed to display the 
phenotype necessary to develop metastatic growth (22, 23). 
Of that fraction, only a few cells are responsible for originating 
secondary growth. It is therefore reasonable to speculate that 
appropriate administration of soluble adhesion molecules, 
which block tumor cell interaction with endothdium or sub- 
strate, may contribute to limiting hematogenous tumor dis- 
semination. The present experiments were designed to test 
the tumor dissemination and growth-blocking effectiveness 
of CD44Rg under conditions that strongly favor tumor de- 
velopment, by introducing large numbers of tumor cells into 
immunocompromised animals.  To maximize the potential 
tumor-inhibiting action of CD44Rg, it was judged appro- 
priate to inject the fusion protein and the tumor cells simul- 
taneously. Although additional investigation will be neces- 
sary to determine whether soluble CD44 may have a clinical 
value as an auxiliary therapeutic reagent, the present obser- 
vations suggest that CD44Rg may provide a useful tool for 
the study of tumor growth in vivo, as well as a potential 
means of controlling dissemination of CD44H  ~sh lymphoid 
malignancies. 
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